GLP-1 USE ASSOCIATED WITH PROTECTION AGAINST GLAUCOMA, CME AND ESPECIALLY AMD.

 

A retrospective cohort study presented at ARVO 2026, which suggests that GLP-1 receptor agonists (such as semaglutide, tirzepatide, and liraglutide) may offer protective benefits for eye health in non-diabetic adults with a BMI of 27 or higher.

Key Findings

The study compared over 31,000 patients using these medications for weight loss against a matched group with no GLP-1 prescriptions. Over a four-year period, those on GLP-1 drugs showed a reduced risk for several major ocular conditions:

  • Significant Reductions: The most robust protection was seen against Age-Related Macular Degeneration (AMD), both dry and wet forms.

  • Glaucoma Protection: Use was associated with a strong reduction in the risk of both primary open-angle and angle-closure glaucoma.

  • Macular Health: There was a moderate decrease in the incidence of cystoid macular edema (CME).

  • Surprising Results: Contrary to some previous studies, this data showed a slight reduction in the risk of NAION (non-arteritic ischemic optic neuropathy).

Conclusion

While research has previously focused on diabetic patients, these findings suggest that the anti-inflammatory or metabolic effects of GLP-1 therapies may provide broad "protective signals" for the eyes of non-diabetics. Researchers emphasize that more longitudinal studies are needed to understand the exact biological mechanisms behind these results.

Comments

Popular posts from this blog

IMPLANTABLE COLLAMER LENS APPEARS BETTER THAN LASIK OR PRK FOR MODERATE TO HIGH MYOPIC PATIENTS

Keratoconus and Inflammatory Skin Conditions

RINSING YOUR CONTACT LENS CASE IS NOT ENOUGH